Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;27(3):111-121.

2019 update of the drug resistance mutations in HIV-1

Annemarie M Wensing  1 , Vincent Calvez  2 , Francesca Ceccherini-Silberstein  3 , Charlotte Charpentier  4 , Huldrych F Günthard  5 , Roger Paredes  6 , Robert W Shafer  7 , Douglas D Richman  8
Affiliations

2019 update of the drug resistance mutations in HIV-1

Annemarie M Wensing et al. Top Antivir Med. 2019 Sep.

Abstract

The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last published in January 2017. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Display of the Figure Bar: Amino acid position, wild type, mutation conferring resistance, and indication of insertion mutation.
None
None
None
None
See this image and copyright information in PMC

References

    1. Wensing AM, Calvez V, Gunthard HF, et al. 2017 Update of the Drug Resistance Mutations in HIV-1. Top Antivir Med. 2017; 24(4):132–133. - PMC - PubMed
    1. Gilead Sciences Inc. BIKTARVY [prescribing information]. 2018. Foster City, CA, Gilead Sciences, Inc.
    1. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101): 1499–1510. - PubMed
    1. Merck & Co Inc. Doravirine [prescribing information]. 2018. Whitehouse Station, NJ, Merck.
    1. Lam E, Parkin NT. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation. Clin Infect Dis. 2003; 37(9):1273–1274. - PubMed

References to the User Notes

    1. von Wyl V, Ehteshami M, Demeter LM, et al. HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin Infect Dis. 2010; 51(5):620–628. - PubMed
    1. Gupta S, Vingerhoets J, Fransen S, et al. Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob Agents Chemother. 2011;55(6):2872–2879. - PMC - PubMed
    1. Rimsky L, Van Eygen V, Vingerhoets J, Leijskens E, Picchio G. Reverse transcriptase connection domain mutations were not associated with virological failure or phenotypic resistance in rilpivirine-treated patients from the ECHO and THRIVE Phase III trials (week 96 analysis). Antivir Ther. 2012;17(Suppl 1):A36.
    1. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837–846. - PubMed
    1. Harrigan PR, Stone C, Griffin P, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis. 2000;181(3):912–920. - PubMed

Substances